News

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...
The large-scale study focused on use of semaglutide and non-GLP-1 RAs. An increased risk for nonarteritic anterior ischemic optic neuropathy with semaglutide was seen at 2, 3 and 4 years from the ...
Semaglutide, the medication better known as Ozempic, reduces the symptoms of a condition that can lead to lower limb amputations in people with diabetes, according to a new study that reinforces ...